Accueil
tpex

Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting

Par un écrivain mystérieux

Description
Fig. 5. Overall survival comparing TPEx regimen and EXTREME regimen - "Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting"
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Highlights from ASCO 2019: A Low-Fat Diet and Breast Cancer Risk
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
ASCO 2022: Equity, innovation and in-person
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
MyFirstASCO: Memories from 57 years of annual meetings - The
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Memorial Sloan Kettering Cancer Center at ASCO 2023
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
What Can Be Learned from a Negative Clinical Trial? Findings from
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
ASCO Annual Meeting 2019: Treatment Advances for Metastatic
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
American Society of Clinical Oncology Policy Statement Update: The
Figure 5 from Highlights for the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting
Recap of Largest-Ever American Society of Clinical Oncology
depuis par adulte (le prix varie selon la taille du groupe)